Gryphon Financial Partners LLC Sells 1,374 Shares of Edwards Lifesciences Co. (NYSE:EW)

Gryphon Financial Partners LLC reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 31.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,946 shares of the medical research company’s stock after selling 1,374 shares during the period. Gryphon Financial Partners LLC’s holdings in Edwards Lifesciences were worth $218,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $555,939,000. Assenagon Asset Management S.A. grew its stake in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after buying an additional 3,506,886 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after buying an additional 2,606,950 shares during the last quarter. Finally, Seilern Investment Management Ltd purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $109,490,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock worth $2,799,104 in the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 0.3 %

EW opened at $71.37 on Tuesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a fifty day moving average price of $72.58 and a 200-day moving average price of $70.32. The firm has a market cap of $42.09 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 4.82 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. The Goldman Sachs Group raised their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.